MedPath

Tagged News

Pluto Bio Secures $3.6M to Expand AI-Powered Platform for Drug Discovery

Precision MedicineAIDrug Discovery
• Pluto Bio has raised $3.6 million in new funding led by Kickstart, with participation from existing investor Silverton Partners, to scale its AI-powered computational biology platform.
• The platform enables scientists to analyze complex biological datasets without coding, supporting critical drug discovery processes including target identification, mechanism of action studies, and precision medicine research.
• Funding will accelerate development of AI agents and copilots, expand integrations with R&D tools, and support commercial growth across therapeutic areas.

Prevencio's AI-Powered Blood Test for Coronary Artery Disease Receives FDA Breakthrough Device Designation

AI
  • The FDA has granted Breakthrough Device Designation to Prevencio's HART CADhs test, an AI-based multi-protein blood test for detecting obstructive coronary artery disease.
  • HART CADhs demonstrated superior accuracy with 0.86 AUC compared to standard-of-care tests like stress echocardiography and nuclear imaging which achieved only 0.52 AUC.
  • The designation enables expedited FDA review to advance the test from a 2-10 day Lab Developed Test to a rapid one-hour FDA-cleared diagnostic for emergency room use.
  • The breakthrough addresses critical diagnostic gaps in cardiovascular care, particularly important given that nearly half of U.S. counties lack access to a cardiologist.

Moderna Partners with IBM to Advance mRNA Drug Discovery Through Quantum Computing and AI

AIDrug Discovery
  • Moderna has formed a strategic partnership with IBM to leverage quantum computing and generative artificial intelligence for advancing mRNA medicine discovery and development.
  • The collaboration aims to deepen understanding of mRNA molecular behavior, refine molecular structures, and improve lipid nanoparticle delivery systems used in mRNA therapeutics.
  • Moderna joins a growing group of pharmaceutical companies including Biogen and Bayer that are embracing quantum computing technologies to accelerate drug discovery processes.
  • The partnership positions Moderna to harness quantum computing's potential to investigate larger molecules and solve previously intractable problems in mRNA research.

ImmunoPrecise's LENSai Platform Achieves X-Ray Crystallography-Level Epitope Mapping Accuracy in Hours

AI
  • ImmunoPrecise Antibodies' LENSai platform matched the performance of x-ray crystallography in epitope mapping using sequence data alone, achieving predictive scores of AUC 0.79-0.89 while reducing turnaround time from weeks to hours.
  • The AI-powered platform demonstrated true generalization by accurately predicting binding sites on 17 previously unseen antibody-antigen complexes, proving it can work beyond its training data without requiring expensive wet-lab experiments.
  • This breakthrough addresses critical industry challenges where over 95% of drug candidates fail before reaching the clinic, offering pharmaceutical companies a faster, more cost-effective method for antibody discovery and development.

Kouper Emerges from Stealth with $10M to Transform Hospital Discharge Care Transitions

AI
  • Kouper launched with $10 million in funding from General Catalyst, 25Madison, and CVS Health Ventures to address care transition failures that cost the U.S. over $53 billion annually in avoidable readmissions.
  • The AI-powered platform integrates directly with hospitals to track patients in real-time after discharge, automating scheduling and surfacing red flags without adding workload for clinical teams.
  • Early health system partners including LifePoint, Henry Ford Health, and Ascension Saint Thomas have reported over 50% increase in patient engagement and 60% improvement in follow-up appointment rates.
  • The company can deploy its platform in under four weeks and is working with several leading health systems to scale its transitions of care infrastructure nationwide.

Digital Health Technologies and AI Show Promise for Transforming Lysosomal Storage Disorder Care in Europe

AI
  • A pioneering European initiative led by Professor Maurizio Scarpa explores integrating digital health innovations including AI, telemedicine, and connected care technologies into care pathways for Lysosomal Storage Disorders.
  • The project aims to address significant challenges in LSD care including delayed diagnoses, fragmented care pathways, and limited access to specialist care through digital health transformations.
  • Digital health technologies offer transformative opportunities to enable earlier intervention, enhance care coordination, and empower patients and healthcare providers with innovative tools.
  • The initiative emphasizes the need for continued generation of high-quality clinical evidence, health economic impact assessment, and multi-stakeholder engagement to optimize care pathways and clinical outcomes.

Insilico Medicine Secures $123 Million Series E Funding to Advance AI-Driven Drug Discovery Pipeline

AIDrug Discovery
  • Insilico Medicine closed an oversubscribed Series E financing round totaling $123 million, led by Value Partners Group, to advance its AI-driven drug discovery platform and clinical pipeline.
  • The company has built a pipeline of over 30 assets with 10 receiving IND clearance, including rentosertib for idiopathic pulmonary fibrosis currently in Phase 2a trials.
  • Insilico filed for its third Hong Kong IPO attempt in 2025, following previous filings in September 2024, amid growing investor interest in AI biotech companies.
  • The funding will support clinical validation of AI-driven drug programs and further development of the company's Pharma.AI platform and automated laboratory capabilities.

AI-Powered Pathology: Transforming Cancer Diagnostics and Precision Oncology

AIOncology
  • AI technology is poised to revolutionize cancer diagnostics by improving accuracy, efficiency, and workflow, while handling tedious tasks that pathologists find challenging or time-consuming.
  • Experts emphasize that AI will not replace pathologists but rather serve as a powerful tool that can provide insights beyond human capability, potentially predicting treatment responses better than current methods.
  • The integration of AI in pathology faces challenges including the need for digitized slides, regulatory hurdles, and ethical considerations, though it promises to standardize diagnoses and reduce disparities in cancer care globally.

Dawn Health Secures €11.5 Million to Expand Pharma-Focused Digital Health Platform

AIReal World EvidenceOncologyRare Disease
  • Copenhagen-based Dawn Health has raised €11.5 million from existing investors to scale its regulatory-grade digital health platform designed specifically for pharmaceutical companies.
  • The platform, already utilized by industry leaders like Merck and Novartis, supports patients with conditions including oncology, multiple sclerosis, and rare pediatric diseases through AI-driven symptom tracking and clinical integration.
  • This funding will accelerate Dawn Health's SaaS delivery model, product development, and international expansion as the company aims to become the global leader in pharmaceutical digital health solutions.

NewLimit Secures $130M Series B to Advance Epigenetic Reprogramming for Age Reversal

AI
• Biotechnology startup NewLimit, co-founded by Coinbase CEO Brian Armstrong, has raised $130 million in Series B funding led by Kleiner Perkins to develop therapies that reverse cellular aging.
• The company has developed three prototype medicines that can reprogram liver cells, demonstrating in laboratory experiments that aged cells can regain youthful characteristics in processing fat and alcohol.
• NewLimit combines AI-driven analysis with large-scale genomics in its "Discovery Engine," which tests thousands of reprogramming combinations on human cells to identify potential age-reversing treatments.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.